Post-myocardial infarction hormone therapy revisited.

Area of Science:

• Cardiology
• Endocrinology
• Women's Health

Background:

• Current guidelines advise against postmenopausal hormone therapy (HT) for secondary prevention of coronary heart disease (CHD).
• Existing recommendations suggest discontinuing HT upon acute coronary events, including myocardial infarction (MI).

Purpose of the Study:

• To review the evidence regarding the discontinuation of hormone therapy in patients post-myocardial infarction.
• To evaluate the basis for current guidelines on stopping HT after an acute coronary event.

Main Methods:

• Literature review of studies examining hormone therapy use and cessation in post-MI patients.
• Analysis of data comparing outcomes for women who continued versus discontinued HT after MI.

Main Results:

• Evidence suggests that stopping hormone therapy post-MI offers no clear benefit.
• Cessation of HT may be associated with adverse cardiac events compared to continuation.
• The basis for current guideline recommendations is not strongly supported by available data.

Conclusions:

• Long-term hormone therapy users should not automatically discontinue treatment after myocardial infarction.
• Individualized patient evaluation is essential for making decisions about HT continuation post-MI.
• Further research may be needed to clarify optimal HT management in post-MI patients.